Clinical trials: Small Bowel Adenocarcinoma, active
Small Bowel Adenocarcinoma
Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care
Small bowel adenocarcinoma is a rare malignancy, and there is limited knowledge about its optimal clinical management and molecular background.
- Trial name
- SBAMOL (NCT06234306)
- Where
- 3 sites in Denmark
- Volunteers
- 500 people
- Sponsor
- Copenhagen University Hospital at Herlev
Colorectal Cancer, Small Bowel Adenocarcinoma
GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas
This is an open-label, non-randomized, single-center, dose-escalation Phase 1 trial using a heterologous prime-boost strategy of vaccination with Ad5.F35-hGUCY2C-PADRE and recombinant Listeria monocytogenes (Lm-GUCY2C) vaccines…
- Trial name
- NCT07417488
- Testing
- Ad5.F35-hGUCY2C-PADRE vaccine, Lm-GUCY2C vaccine, CT Scan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Thomas Jefferson University
Small-bowel Adenocarcinoma, Metastatic Disease
First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma
Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma
- Conditions
- Small-bowel Adenocarcinoma, Metastatic Disease, Chemotherapy Effect
- Trial name
- FIRE-12 (NCT07844057)
- Testing
- mFOLFIRINOX versus FOLFOX chemotherapy
- Where
- 16 sites in Germany
- Volunteers
- 86 people
- Sponsor
- Annika Kurreck
Esophageal Carcinoma, Gastric Cancer (Diagnosis)
Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)
This is a phase II open-label, basket clinical trial to assess the feasibility of systemic and Intraperitoneal chemotherapy in subjects with Gastrointestinal Malignancies with Peritoneal Carcinomatosis.
- Conditions
- Esophageal Carcinoma, Gastric Cancer (Diagnosis), Colorectal Adenocarcinoma, Appendiceal Adenocarcinoma
- Trial name
- NCT07795749
- Testing
- Paclitaxel Q2W, Paclitaxcel Q3W
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of California, Irvine
Small Bowel Adenocarcinoma
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
The study regimen will be administered on an outpatient basis and all medications are administered intravenously (IV). Subjects will receive treatment on Day 1 and Day 15 of each 28-day cycle consisting of the following…
- Trial name
- NCT06835387
- Testing
- Nanoliposomal irinotecan, Oxaliplatin, 5 fluorouracil
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Tiago Biachi de Castria
Advanced Small Bowel Adenocarcinoma
Sacituzumab Tirumotecan (MK-2870) in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-Based Combination Therapy
Small bowel adenocarcinoma is a rare cancer with a poor prognosis. For patients with locally advanced or metastatic disease, the usual first treatment is chemotherapy with platinum-based combinations such as FOLFOX or CapeOX.
- Trial name
- METROPOLIS (NCT07720258)
- Testing
- Sacituzumab tirumotecan
- Where
- 5 sites in Japan
- Volunteers
- 27 people
- Sponsor
- National Cancer Center, Japan
Lynch Syndrome, Lynch Syndrome I
Videocapsule Endoscopy in Lynch Syndrome
Background Lynch syndrome is caused by a pathogenic variant in one of the four Mismatch Repair genes (MMR): MLH1, MSH2/Epcam, MSH6, or PMS2.
- Conditions
- Lynch Syndrome, Lynch Syndrome I, Lynch Syndrome II, MLH1 Gene Mutation
- Trial name
- NCT05704010
- Testing
- Video capsule endoscopy
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- San Raffaele University
MMR Mutation, Small Bowel Adenoma
Small Bowel Capsule Endoscopy in Lynch Syndrome
The impact of small bowel (SB) capsule endoscopy (CE) on the screening (followed by diagnosis and treatment) of (pre)neoplastic lesions of the small bowel in Lynch syndrome (LS) patients is unknown.
- Conditions
- MMR Mutation, Small Bowel Adenoma, Small-bowel Adenocarcinoma, Lynch Syndrome
- Trial name
- iCARE4Lynch (NCT07472686)
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced Small Bowel Adenocarcinoma
Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy
Small bowel adenocarcinoma is a rare cancer with a poor prognosis. For patients with locally advanced or metastatic disease, the usual first treatment is chemotherapy with platinum-based combinations such as FOLFOX or CapeOX.
- Trial name
- ENVELOPE (NCT07347314)
- Testing
- Enfortumab vedotin
- Where
- 3 sites in Japan
- Volunteers
- 27 people
- Sponsor
- National Cancer Center, Japan
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
The goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for deficient mismatch repair (dMMR)/microsatellite…
- Conditions
- Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma
- Trial name
- Pan-MSI-ACSE (NCT06333314)
- Testing
- Dostarlimab, Chemotherapy
- Where
- 22 sites in France
- Volunteers
- 120 people
- Sponsor
- UNICANCER
Locally Advanced or Metastatic Small Bowel Adenocarcinoma
Trial Evaluating Modified FOLFIRINOX and Modified FOLFOX in the Treatment of Locally Advanced or Metastatic Small Bowel Adenocarcinoma
Randomized, non-comparative, open-label, multi-centre Phase II study to evaluate modified FOLFIRINOX and modified FOLFOX in the locally advenced or metastatic small bowel adenocarcinoma.
- Trial name
- FOLFORINOX SBA (NCT06278545)
- Testing
- modified FOLFORINOX, Modified FOLFOX
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Centre Hospitalier Universitaire Dijon